New radioactive 'Smart Bomb' targets Hard-to-Treat lung cancer
NCT ID NCT07278479
First seen Jan 07, 2026 · Last updated Jun 22, 2026 · Updated 26 times
Summary
This study tests a new drug that delivers radiation directly to cancer cells carrying a protein called DLL3, found in small cell lung cancer and other solid tumors. The trial enrolls 138 adults whose cancer has progressed after at least two prior treatments. The goal is to check safety, find the right dose, and see if the drug can shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER (SCLC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Emory University Hospital
RECRUITINGAtlanta, Georgia, 30322, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Nebraska Cancer Specialists
RECRUITINGOmaha, Nebraska, 68130, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
United Theranostics
RECRUITINGGlen Burnie, Maryland, 21061, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
United Theranostics
RECRUITINGPrinceton, New Jersey, 08540, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University Hospitals Cleveland Medical Center
RECRUITINGCleveland, Ohio, 44106, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
A radioactive drug that targets DLL3 on cancer cells
What this could lead to
If it works, this could provide a new treatment option for people with advanced small cell lung cancer that has stopped responding to standard therapies.
What could go wrong
This is an early-phase trial (phase 1/2a) with a small number of participants, so the drug may not prove effective or safe enough for wider use. Radiation-based drugs can cause side effects like damage to healthy tissues.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.